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I.    INTRODUCTION 
A mutation in a protein-coding gene in DNA can alter the 
protein structure coded  by  the  same  gene.  Structurally 
altered proteins usually lose their functions and sometimes 
gain an undesirable function instead. These types of muta-
tions and their effects can result in genetic diseases or antibi-
otic resistant bacteria, among other health issues. Important 
curing methods have been developed by detecting mutations 
against AIDS as well as genetic diseases ([1]; [2]). Another 
example is the influenza virus. The reasons why a vaccina-
tion developed to fight against influenza does not work the 
following year are (a) the mutation of its DNA and (b) the 
outbreak of the virus after it has been mutated especially if it 
is a virus that escaped the vaccinations target ([3]). Due to 
such reasons it is highly important to know in advance the 
location of a potential mutation in a protein as well as the 
problems it might cause the medical sciences. 
Like  other  diseases  mentioned,  cancer  also  appears  as 
a  result  of  a  growing  cell  or  a  mutation  of  accumulated 
proteins that are actually in charge of the controlled death of 
a cell (apoptosis). The uncontrolled growth of a cell or its 
uncontrolled division creates a tumor. In a healthy person 
these minor tumors are constantly created. A wholly function-
ing p53 protein stops cancer by killing the cells converted 
into tumors in a controlled way or by preventing the genes, 
which are in charge of the division, expressing themselves 
(Figure 1) ([4]; [5]; [6]). A p53 protein, which has such a 
critical role in preventing cancer, can also be the cause of it 
when it loses its functions due to a mutation. If the phenotyp-
ic functions of these mutations can be foreseen, a ground-
breaking cancer cure can be developed with a smart and tar-
get oriented medicine design. Although some types of cancer 
cures are dependent on pharmacological studies, they are 
usually centered around casting light on the mutational rea-
sons for the cancer. 
Predicting the results of a mutation in any amino acid 
within a protein depends on the estimation of the mutations 
effect on the protein structure. This is already a very diffi-
cult task. It gets even harder combinatorically when multi-
ple mu- tations occur at the same time. For instance, a p53 
protein that consists of 393 amino acids (taking into con-
sideration that each amino acid can transform into any one 
of the 19 amino acids) gives us a wide configuration of 
approximately 19
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4 0 0 
. In a problem where the possibil-
ities of mutation configurations are  increasing  exponen-
tially,  even  if  1000  mutations  were tested per day, all the 
days of the universe would not be sufficient enough. And 
even if each experiment would cost just 1 cent, all the mon-
ey in the world would not be enough to test them all. There-
fore, we need a sensitive and a strong computational algo-
rithm that has the skills to generalize rules even from a tiny 
sample. 
!  
Fig. 1.    p53 protein and its amino acids that interact with 
DNA 
In the name of developing computational algorithm, the In 
ternational Agency for Research on Cancer (IARC) published 
a TP53 mutation database that contains 31,420 different p53 
gene mutations that are diagnosed in cancer patients ([7]; 
[8]). Approximately 70% of these wide mutation configura-
tions are due to one single amino acid mutation that takes 
place where p53 binds to DNA. Although it is highly crucial, 
the complete structure of p53 protein remains undiscovered. 
We can only create  homological models  through  biophysi-
cal simulations since we only know the crystal structure of 
the functional region  of  p53  ([9];  [10]).  We  can  also 
only  calculate  the effects of a mutation of a protein on a 1 
dimensional sequence, a  2  dimensional  electronegativity 
surface  profile and  in  3 dimensional amino acid locations. 
These calculations do not give us enough idea on the func-
tions of a  direct mutation since  the  organization of  amino 
acids  in  a  p53  protein  is highly complex and has synergis-
tic relationships. We can briefly define the problem of cate-
gorizing the p53 mutations as follows: to foresee whether a 
p53 protein is active or inactive as a result of alterations in a 
given series of amino acids. 
There have been studies in the field of classic machine 
learning and statistical techniques ([10]; [11]). However, their 
performances have so far been far below expectations. One 
of the important reasons of this low performance is because 
they have overlooked which amino acids are important in 
provided data, the approach of heuristic algorithm with evo-
lutional com- parisons, and the interactions in between linear 
dimensional reduction methods and nonlinear relationships. 
Artificial intelligence studies have shown ground break-
ing developments  in  recent  years  thanks  to  capacity  in-
creases in computer technology and their ability to access all 
sorts of  data  ([12]).  The  most  important  development  of 
all  is neural networks models. These models can learn the 
necessary characteristics from the provided data by them-
selves in order to foresee the result. This method, known as 
deep learning, facilitates our lives and provides us with dri-
verless cars, voice recognition systems, visual analysis and 
unmanned aircrafts among others and resolves our daily 
problems ([13]). By applying artificial intelligence to medi-
cine and genetics great problems have been overcome in bi-
ology in recent years ([14]; [15]; [16]; [17]; [18]). 
In this study we have used artificial neural networks, 
which are  one  of  the  latest  artificial intelligence technolo-
gies, to determine the effects of cancer mutations. The model 
we developed  has  given  more  successful  results  com-
pared  to other methods. We foresee that our model will bring 
a new dimension to medical research and the medicine indus-
try. 
II.    METHOD 
We  downloaded  data  provided  by  the  IARC  that  con- 
sisted of 31,420 different p53 mutations from the California 
University  Irvine  archives  ([19]).  In  each  data  set  which 
has multivariate characteristics, there are 5,409 features for 
each mutation. 2,510 of these scores feature a 1 dimensional 
sequence of the mutated protein ([20]), 2,316 score features 
of 2 dimensional electronegative and the remaining 582 score 
3 dimensional position features (Figure 2). 
First of all, without altering the order of this data, 1 di-
mensional, 2 dimensional and 3 dimensional features were 
recorded separately in  a  hierarchical data format (hdf5) as 
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Fig. 2.   Characteristics of the input data. (a) 1 dimensional features 
(Adapted from [20]). (b) 2 dimensional features, blue color indicates 
positive charge and red color indicates negative charge. (c) 3 dimensional 
features, boxes indicate 3 dimensional distances to a healthy version of 
p53 amino acids in a mutational condition. As the box gets whiter it 
indicates that it is getting further away from its healthy condition (Image 
adapted from [10]). 
developed by NASA for large dimensional data. Since 92% 
of the data was negative, positive (active) and negative 
(inactive) sets were not balanced. When we trained our 
model with an unbalanced set, it only gave negative results. 
Therefore, during the training of the model we fed it with 
an equal amount of positive and negative samples. We di-
vided the data into two; 
2000 tests and 29,420 training data. The test data model 
was not used during the training period; it was only used to 
trial the model. 
We wrote our model in Python language with the Ten-
sor- flow deep learning package ([21]). We connected our 
model, which has 2 convolutional and 2 complete connec-
tion layers, to a 2 neuron output. We determined the activa-
tion function of neurons in each layer (except from the final 
layer) as a rectified linear unit (ReLU), and in the final lay-
er as hyperbolic tangent (tanh). We made it  have a  possi-
ble distribution of  a  mold total of 1. We did this by filter-
ing the 2-neuron-output through softmax, thus having neu-
ron values in between 0 and 1. We then coded the active 
mutations as [1,0] and inactive mutations as [0,1]. We de-
termined our loss function as categorical cross entropy, 
which is widely used for binary categorization, to train the 
neurons in an artificial neural network model. We evaluated 
the training of the model by showing the data over and over 
again and by looking at the changes to loss function over 
time. Each training time took approximately 10 minutes in 
a standard laptop. 
In order to compare our deep learning model that we 
adopted from the field of artificial intelligence to other 
mod- els that have been used until recent years, we utilized 
the scikitlearn package ([22]). We  also  applied Support 
Vector Machines (SVM) and Logistic Regression models. 
III.    FINDINGS 
First  of  all,  we  trained  our  model  individually  for 
a mutated proteins 1 dimensional, 2 dimensional and 3 di- 
mensional features.  We  later  on  tried  it  on  test  data. 
The performance alteration over the samples given to the 
model can be seen in Image 3. If we foresaw it completely 
randomly, the performance would be 50% as we tested it on 
an equal amount of positive and negative data. As can be 
viewed in the  image, the  final precision levels  of  predict-
ing mutated protein activity stand at 76%, 89% and 85% 
respectively, and they are higher compared to random pre-
dicting levels. Since our  model  was  developed  on  the 
basis  of  artificial neural networks, we can easily combine 
different input categories and create a combined model with 
a higher capacity. When we trained this combined model, 
we obtained a better performance (98%) than  the  ones 
obtained in  the  single input category (Figure 3). In  order 
to  compare our model based on deep 
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Fig.  3.      Performance of  trained  models  of  different  input  data 
features according to iteration. 
learning to other machine learning techniques, we catego-
rized the same data by using Support Vector Machines 
(SVM) and Logistic Regression from the same scikitlearn 
package ([22]). We optimized hyper parameters with grid 
search and reached a level of 73% precision with SVM and 
62% precision with Logistic Regression (4a). This proves 
that our model has a higher success rate compared to oth-
ers. 
Categorizing p53 mutations have been studied but dif-
ferent methods have been used ([10]; [23]). In a similar 
way, when we compared our model to similar studies we 
noticed that in each input category our models performance 
is significantly higher (Figure 4b). 
The final layer of our deep learning model has a 2-neu-
ron- output that tells us whether the mutation is active or 
inactive. The penultimate layer provides a representation of 
data which is complex and with intricate features. We visu-
alized active and inactive data in order to show that our 
models input data features, which are in complex interac-
tion among themselves, can be transformed to a compre-
hendible representation space by Principal Component 
Analysis (PCA) and t-distributed Stochastic Neighbor Em-
bedding (t-SNE) methods (Figure 5) ([24]).  As  can  be 
viewed,  the  models  representation layer projected the 
complex input into a comprehendible space that can easily 
categorize it. 
IV.    RESULTS AND DISCUSSION 
p53  protein mutations, which play  an  instrumental 
role in various types of cancer and have been studied thou-
sands of times as it is highly important for the medical 
world to understand them, and what type of results they 
would produce, could not be foreseen satisfactorily up until 
now. In this study we applied the artificial neural network, 
which is one of the latest technologies in artificial intelli-
gence, to p53 mutations in order to foresee problems. We 
discovered that our model has a higher performance and a 
higher success rate compared to  
Fig. 4.    Comparison of our model to (a) other common techniques 
(SVM, Linear Regression) and (b) previous academic studies. 
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Fig. 5.     Visualization of our model by (a) PCA and (b) low dimen-
sional t-SEN in a representational layer. Active and inactive samples that 
cannot be separated in an input layer can be separated clearly in a repre-
sentation layer. 
not only the two other widely used methods, but also to 
other formerly published academic studies. Since our mod-
el is based on artificial neural networks, it can combine 
different modules in a much easier way, and, in doing, so 
we can obtain a more developed combined model. We have 
proved that our combined model is more successful than 
the single input models. 
Since the number of all p53 mutated types is vast, the 
active or inactive condition of all mutations cannot be 
stored in a database. Therefore, oncologists or geneticist 
doctors should use an acute computer program like the one 
we offer to foresee the results once they sequence the pa-
tients TP53 gene. On the other hand, our model is not only 
authentic for p53 protein. There are hundreds of other pro-
teins that cause genetic diseases, and a similar model can be 
manufactured for each one. Furthermore, medicine design-
ers can produce medicine that can be bound to the active 
part of a protein of their interest. Our artificial intelligence 
approach determines which part of a protein is active by 
categorizing mutations, thus offering a solution on this mat-
ter. When all of these aspects are considered, we can see the 
potential benefits and the use of our model in fields such as 
medicine and pharmacology.  
In future, since our study can be applied to other genetic 
diseases based on mutation, we think that it will be recom- 
mendable to create different databases for future studies as 
IARC has done for p53. 
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